The burden of diseases and risk factors in Bangladesh, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
16
03
2023
revised:
07
08
2023
accepted:
06
09
2023
medline:
27
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
ppublish
Résumé
Bangladesh has made substantial progress in improving socioeconomic and health indicators over the past 50 years, but data on national disease burden are scarce. We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to estimate the burden of diseases and risk factors in Bangladesh from 1990 to 2019. For this systematic analysis, we analysed data from vital registration systems, surveys, and censuses using multistage modelling processes to estimate life expectancy at birth, mortality rate, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs). Additionally, we compared the health status of Bangladesh with that of the other countries in the GBD south Asia region-Bhutan, India, Nepal, and Pakistan. Life expectancy at birth in Bangladesh increased from 58·2 years (95% uncertainty interval 57·1-59·2) in 1990 to 74·6 years (72·4-76·7) in 2019. Between 1990 and 2019, the age-standardised mortality rate decreased from 1509·3 (1428·6-1592·1) to 714·4 (604·9-838·2) deaths per 100 000 population. In 2019, non-communicable diseases represented 14 of the top 20 causes of death; the leading three causes were stroke, ischaemic heart disease, and chronic obstructive pulmonary disease. High blood pressure, high fasting plasma glucose, and smoking were the top three risk factors. From 1990 to 2019, the rate of all-cause DALYs decreased by 54·9% (48·8-60·4). In 2019, the leading causes of DALYs and YLLs were neonatal disorders, stroke, and ischaemic heart disease, whereas musculoskeletal disorders, depressive disorders, and low back pain were the leading causes of YLDs. Bangladesh has the lowest age-standardised rates of mortality, YLDs, and YLLs and the highest life expectancy at birth in south Asia. Over the past 30 years, mortality rates have reduced by more than half in Bangladesh. Bangladesh must now address the double burden of communicable and non-communicable diseases. Cost-effective, multisectoral efforts are needed to prevent and control non-communicable diseases, promote healthy lifestyles, and prevent premature mortality and disabilities. Bill & Melinda Gates Foundation. For the Bangla translation of the abstract see Supplementary Materials section.
Sections du résumé
BACKGROUND
BACKGROUND
Bangladesh has made substantial progress in improving socioeconomic and health indicators over the past 50 years, but data on national disease burden are scarce. We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to estimate the burden of diseases and risk factors in Bangladesh from 1990 to 2019.
METHODS
METHODS
For this systematic analysis, we analysed data from vital registration systems, surveys, and censuses using multistage modelling processes to estimate life expectancy at birth, mortality rate, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs). Additionally, we compared the health status of Bangladesh with that of the other countries in the GBD south Asia region-Bhutan, India, Nepal, and Pakistan.
FINDINGS
RESULTS
Life expectancy at birth in Bangladesh increased from 58·2 years (95% uncertainty interval 57·1-59·2) in 1990 to 74·6 years (72·4-76·7) in 2019. Between 1990 and 2019, the age-standardised mortality rate decreased from 1509·3 (1428·6-1592·1) to 714·4 (604·9-838·2) deaths per 100 000 population. In 2019, non-communicable diseases represented 14 of the top 20 causes of death; the leading three causes were stroke, ischaemic heart disease, and chronic obstructive pulmonary disease. High blood pressure, high fasting plasma glucose, and smoking were the top three risk factors. From 1990 to 2019, the rate of all-cause DALYs decreased by 54·9% (48·8-60·4). In 2019, the leading causes of DALYs and YLLs were neonatal disorders, stroke, and ischaemic heart disease, whereas musculoskeletal disorders, depressive disorders, and low back pain were the leading causes of YLDs. Bangladesh has the lowest age-standardised rates of mortality, YLDs, and YLLs and the highest life expectancy at birth in south Asia.
INTERPRETATION
CONCLUSIONS
Over the past 30 years, mortality rates have reduced by more than half in Bangladesh. Bangladesh must now address the double burden of communicable and non-communicable diseases. Cost-effective, multisectoral efforts are needed to prevent and control non-communicable diseases, promote healthy lifestyles, and prevent premature mortality and disabilities.
FUNDING
BACKGROUND
Bill & Melinda Gates Foundation.
TRANSLATION
UNASSIGNED
For the Bangla translation of the abstract see Supplementary Materials section.
Identifiants
pubmed: 37973341
pii: S2214-109X(23)00432-1
doi: 10.1016/S2214-109X(23)00432-1
pmc: PMC10664824
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1931-e1942Investigateurs
Sheikh Mohammed Shariful Islam
(SMS)
Riaz Uddin
(R)
Subasish Das
(S)
Syed Imran Ahmed
(SI)
Sojib Bin Zaman
(SB)
Sheikh Mohammad Alif
(SM)
Md Tanvir Hossen
(MT)
Malabika Sarker
(M)
George Siopis
(G)
Katherine M Livingstone
(KM)
Max L Mehlman
(ML)
Md Marufur Rahman
(MM)
Rahat I Chowdhury
(RI)
Md Abdul Alim
(MA)
Sohel Reza Choudhury
(SR)
Syed Masud Ahmed
(SM)
Ripon Kumar Adhikary
(RK)
Afifa Anjum
(A)
Palash Chandra Banik
(PC)
Fazle Rabbi Chowdhury
(FR)
Md Omar Faruk
(MO)
Rajat Das Gupta
(RD)
Md Abdul Hannan
(MA)
Md Nuruzzaman Haque
(MN)
Syed Emdadul Haque
(SE)
M Tasdik Hasan
(MT)
Md Belal Hossain
(MB)
Md Mahbub Hossain
(MM)
Muttaquina Hossain
(M)
Sahadat Hossain
(S)
Sheikh Jamal Hossain
(SJ)
M Nuruzzaman Khan
(MN)
Md Jobair Khan
(MJ)
Mohammed A Mamun
(MA)
Ali H Mokdad
(AH)
Mohammad Ali Moni
(MA)
Christopher J L Murray
(CJL)
Mahfuzar Rahman
(M)
Md Mosfequr Rahman
(MM)
Mosiur Rahman
(M)
Zubair Ahmed Ratan
(ZA)
Rezaul Karim Ripon
(RK)
K M Saif-Ur-Rahman
(KM)
Abu Sayeed
(A)
Md Shahjahan Siraj
(MS)
Saima Sultana
(S)
Ralph Maddison
(R)
Simon I Hay
(SI)
Mohsen Naghavi
(M)
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests S M S Islam reports support for this manuscript from an Emerging Leadership Fellowship from the National Health and Medical Research Council of Australia (APP1195406) and Vanguard grants from the National Heart Foundation of Australia. S M S Islam has unpaid roles, outside the submitted work, with the IT Committee of the Cardiac Society of Australia and New Zealand, as a volunteer on the Cardiac Devices Committee of the ESC Heart Failure Association, and as a volunteer topic group leader for the WHO-ITU Global Initiative on AI for Health. K M Livingstone reports support for this manuscript from a National Health and Medical Research Council of Australia grant (APP1173803).
Références
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Lancet Glob Health. 2021 May;9(5):e660-e667
pubmed: 33751956
Int J Clin Pract. 2021 Oct;75(10):e14613
pubmed: 34235819
Lancet. 2013 Nov 23;382(9906):1734-45
pubmed: 24268002
BMJ Open. 2019 Sep 17;9(9):e027896
pubmed: 31530589
Bull World Health Organ. 2015 Nov 1;93(11):806-9
pubmed: 26549909
Elife. 2019 Apr 08;8:
pubmed: 30958263
PLoS One. 2016 Aug 05;11(8):e0160180
pubmed: 27494706
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
BMJ. 2004 Apr 3;328(7443):816-9
pubmed: 15070640
Am J Public Health. 2012 Dec;102(12):2248-54
pubmed: 23078501
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
BMC Public Health. 2015 Feb 28;15:203
pubmed: 25880433
Lancet Diabetes Endocrinol. 2019 Mar;7(3):200-212
pubmed: 30733182
Diabetes Res Clin Pract. 2022 Aug;190:109873
pubmed: 35436546
J Glob Health. 2019 Dec;9(2):020803
pubmed: 31673347
BMJ Open. 2018 Oct 31;8(10):e022817
pubmed: 30385441
J Diabetes Metab Disord. 2021 Feb 15;20(1):417-425
pubmed: 34222069
Lancet. 2013 Nov 23;382(9906):1746-55
pubmed: 24268003
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Lancet Infect Dis. 2017 Sep;17(9):909-948
pubmed: 28579426
Diabetes Care. 2015 Aug;38(8):e112-3
pubmed: 26207059
N Engl J Med. 2020 Feb 20;382(8):717-726
pubmed: 32074419
PLoS One. 2022 May 3;17(5):e0267243
pubmed: 35503777
Lancet. 2017 Jul 15;390(10091):231-266
pubmed: 28528753
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325